Clinical Trial Update: Early Versus Late Ofatumumab (Kesimpta®) Use in Austrian RMS-Patients Over 2 Years

View source ↗

Summary

A clinical trial comparing early versus late use of Kesimpta (ofatumumab) in Austrian patients with relapsing multiple sclerosis, with the study currently activ…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Relapsing Multiple Sclerosis

Drugs mentioned

• Kesimpta (ofatumumab)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Relapsing Multiple Sclerosis | Status: ACTIVE_NOT_RECRUITING